Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 13/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | NAMPT | P43490 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13197389 | 0.90 | CETP (0.48) | CETPPOLBKCNH2 | |
| SCHEMBL2831557 | 0.87 | CETP (0.69) | CETPKCNH2 | |
| SCHEMBL13197461 | 0.86 | CETP (0.60) | CETPKCNH2 | |
| SCHEMBL13232519 | 0.82 | CETP (0.74) | CETPKCNH2 | |
| SCHEMBL13232518 | 0.82 | CETP (0.74) | CETPKCNH2 | |
| SCHEMBL13059706 | 0.82 | CETP (0.70) | CETPKCNH2 | |
| SCHEMBL13204380 | 0.78 | CETP (0.62) | CETPKCNH2 | |
| SCHEMBL2832973 | 0.77 | CETP (0.61) | CETPKCNH2 | |
| SCHEMBL13197397 | 0.77 | CETP (0.51) | CETPKCNH2MAPTHPGDSMN1; SMN2 | |
| SCHEMBL13984008 | 0.76 | CETP (0.50) | CETPPOLBKCNH2NAMPTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436028-B2 | CETP inhibitors derived from benzoxazole arylamides | MERCK SHARP & DOHME CORP (US) | 2013-05-07 | — | — | US | disclosed |
| US-20100197630-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK & CO., INC | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197630-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | CETP, APOB, MTTP | CETP 1/4885POLB 1879/4885KCNH2 3407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.